CDK4 and triple-negative breast carcinoma: A role for CDK4 in glycolysis has been described in mouse embryonic fibroblasts (MEFs), whereby CDK4 knockout impairs anaerobic glycolysis [17], whilst the CDK4/6 inhibitor palbociclib reduces glycolysis in triple-negative breast cancer [40,41] and mesothelioma [42].